I have not read through the entire 10-Q, actually just skimmed the important comments and looked at the financials.

A good quarter looking at the Income Statement, but as I have stated in prior posts, we need a continuation of these numbers every quarter as a minimum, would be nice to see some percent improvement each succeeding quarter.

To breakeven for a year, I still believe we need $11-13 million dollars with most of the revenue coming as direct sales, not through distributors.

The real key to growth, it will be hard to continue with increased revenue in the IFE segment, will be can we begin to market the eVU in added market segments to sustain the growth curve on a long term basis? We need to show revenues coming from non IFE to generate sufficient profits to attract new investors and ultimately uptrend the share price.

The balance sheet as usual, is not very impressive and will probably remain pretty much the same until we see several successful quarters.

Of course, all of the above changes significantly if DM is successful in some or many patent settlements/trials. That income would go directly to the bottom line and the share price would be affected accordingly. I don't even think taxes would be due because of the sizeable losses to date.

Cautious optimism is still the rule of the day.